[{"indications": "Indications\u00a0bacterial skin infections", "name": "NEOMYCIN SULPHATE - ANTIBACTERIAL PREPARATIONS ONLY USED TOPICALLY", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "13 Skin", "13.10 Anti-infective skin preparations", "13.10.1 Antibacterial preparations", "13.10.1.1 Antibacterial preparations only used topically", "NEOMYCIN SULPHATE"], "cautions": "Cautions\u00a0large areas, see belowLarge areas\u00a0If large areas of skin are being treated\r\nototoxicity may be a hazard, particularly in children, in the elderly,\r\nand in those with renal impairment", "side-effects": "Side-effects\u00a0sensitisation (see also notes above)", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/6123.htm", "doses": ["apply up to 3 times daily (short-term use)"]}, {"indications": "Indications\u00a0bowel sterilisation before surgery, see also notes above", "name": "NEOMYCIN SULPHATE - AMINOGLYCOSIDES", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "5 Infections", "5.1 Antibacterial drugs", "5.1.4 Aminoglycosides"], "cautions": "Cautions\u00a0\n(From 5.1.4 Aminoglycosides: British National Formulary)\nCautions\u00a0The main side-effects of the aminoglycosides are dose-related, therefore, care must be taken with dosage, and, whenever possible, parenteral treatment should not exceed 7 days. Renal function should be assessed before starting an aminoglycoside and during treatment. If possible, dehydration should be corrected before starting an aminoglycoside. Auditory and vestibular function should also be monitored during treatment. In order to optimise the dose and avoid toxicity, serum-aminoglycoside concentrations should be monitored in patients receiving parenteral aminoglycosides (see also Serum Concentrations). Ototoxicity and nephrotoxicity occur most commonly in the elderly; therefore, monitoring is particularly important in these patients, who may require reduced doses.Aminoglycosides should be used with caution in those with conditions characterised by muscular weakness (avoid in myasthenia gravis). Aminoglycosides should preferably not be given with potentially ototoxic diuretics (e.g. furosemide); if concurrent use is unavoidable administration of the aminoglycoside and of the diuretic should be separated by as long a period as practicable. Interactions: Appendix 1 (aminoglycosides), but too toxic for systemic use; interactions: Appendix 1 (aminoglycosides)", "side-effects": "Side-effects\u00a0\n(From 5.1.4 Aminoglycosides: British National Formulary)\nSide-effects\u00a0The important side-effects of the aminoglycosides are nephrotoxicity and irreversible ototoxicity (including vestibular and auditory damage). Rash occurs commonly with streptomycin, but less frequently with the other aminoglycosides. Rare side-effects include nausea, vomiting, antibiotic-associated colitis, peripheral neuropathy, electrolyte disturbances (notably hypomagnesaemia on prolonged therapy, but also hypocalcaemia and hypokalaemia), and stomatitis. Side-effects reported very rarely include blood disorders and CNS effects (including headache, encephalopathy, and convulsions). Aminoglycosides may impair neuromuscular transmission; large doses given during surgery have been responsible for a transient myasthenic syndrome in patients with normal neuromuscular function., but poorly\r\nabsorbed on oral administration; increased salivation, impaired intestinal\r\nabsorption with steatorrhoea and diarrhoea", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/3841.htm", "doses": ["By mouth, pre-operative bowel sterilisation,\r\n1\u00a0g every hour for 4 hours, then 1\u00a0g every 4 hours for 2\u20133 days", "Hepatic coma, up to 4\u00a0g daily in divided doses usually for 5\u20137\r\ndays"], "pregnancy": "Pregnancy\u00a0\n(From 5.1.4 Aminoglycosides: British National Formulary)\nPregnancy\u00a0There is a risk of auditory or vestibular nerve damage in the infant when aminoglycosides are used in the second and third trimesters of pregnancy. The risk is greatest with streptomycin (section 5.1.9). The risk is probably very small with gentamicin and tobramycin, but their use should be avoided unless essential (if given, serum-aminoglycoside concentration monitoring is essential)."}, {"breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "11 Eye", "11.3 Anti-infective eye preparations", "11.3.1 Antibacterials", "NEOMYCIN SULPHATE"], "indications": "Indications\u00a0\n(From 11.3.1 Antibacterials: British National Formulary)\n11.3.1 Antibacterials", "name": "NEOMYCIN SULPHATE - ANTIBACTERIALS", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/5393.htm", "doses": ["See Administration in\r\nnotes above"]}, {"indications": "Indications\u00a0bowel sterilisation before surgery, see also notes above", "name": "NEOMYCIN SULPHATE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "5 Infections", "5.1 Antibacterial drugs", "5.1.4 Aminoglycosides"], "cautions": "Cautions\u00a0\n(From 5.1.4 Aminoglycosides: British National Formulary)\nCautions\u00a0The main side-effects of the aminoglycosides are dose-related, therefore, care must be taken with dosage, and, whenever possible, parenteral treatment should not exceed 7 days. Renal function should be assessed before starting an aminoglycoside and during treatment. If possible, dehydration should be corrected before starting an aminoglycoside. Auditory and vestibular function should also be monitored during treatment. In order to optimise the dose and avoid toxicity, serum-aminoglycoside concentrations should be monitored in patients receiving parenteral aminoglycosides (see also Serum Concentrations). Ototoxicity and nephrotoxicity occur most commonly in the elderly; therefore, monitoring is particularly important in these patients, who may require reduced doses.Aminoglycosides should be used with caution in those with conditions characterised by muscular weakness (avoid in myasthenia gravis). Aminoglycosides should preferably not be given with potentially ototoxic diuretics (e.g. furosemide); if concurrent use is unavoidable administration of the aminoglycoside and of the diuretic should be separated by as long a period as practicable. Interactions: Appendix 1 (aminoglycosides), but too toxic for systemic use; interactions: Appendix 1 (aminoglycosides)", "side-effects": "Side-effects\u00a0\n(From 5.1.4 Aminoglycosides: British National Formulary)\nSide-effects\u00a0The important side-effects of the aminoglycosides are nephrotoxicity and irreversible ototoxicity (including vestibular and auditory damage). Rash occurs commonly with streptomycin, but less frequently with the other aminoglycosides. Rare side-effects include nausea, vomiting, antibiotic-associated colitis, peripheral neuropathy, electrolyte disturbances (notably hypomagnesaemia on prolonged therapy, but also hypocalcaemia and hypokalaemia), and stomatitis. Side-effects reported very rarely include blood disorders and CNS effects (including headache, encephalopathy, and convulsions). Aminoglycosides may impair neuromuscular transmission; large doses given during surgery have been responsible for a transient myasthenic syndrome in patients with normal neuromuscular function., but poorly\r\nabsorbed on oral administration; increased salivation, impaired intestinal\r\nabsorption with steatorrhoea and diarrhoea", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/3841.htm", "doses": ["By mouth, pre-operative bowel sterilisation,\r\n1\u00a0g every hour for 4 hours, then 1\u00a0g every 4 hours for 2\u20133 days", "Hepatic coma, up to 4\u00a0g daily in divided doses usually for 5\u20137\r\ndays"], "pregnancy": "Pregnancy\u00a0\n(From 5.1.4 Aminoglycosides: British National Formulary)\nPregnancy\u00a0There is a risk of auditory or vestibular nerve damage in the infant when aminoglycosides are used in the second and third trimesters of pregnancy. The risk is greatest with streptomycin (section 5.1.9). The risk is probably very small with gentamicin and tobramycin, but their use should be avoided unless essential (if given, serum-aminoglycoside concentration monitoring is essential)."}]